{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["St. John\u2019s wort extract (SJW)", "pyrrolizidine alkaloids (PA)", "risk-benefit analysis"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "29932143", "DateCompleted": {"Year": "2019", "Month": "01", "Day": "07"}, "DateRevised": {"Year": "2023", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "06", "Day": "22"}], "Language": ["eng"], "ELocationID": ["804", "10.3390/nu10070804"], "Journal": {"ISSN": "2072-6643", "JournalIssue": {"Volume": "10", "Issue": "7", "PubDate": {"Year": "2018", "Month": "Jun", "Day": "22"}}, "Title": "Nutrients", "ISOAbbreviation": "Nutrients"}, "ArticleTitle": "A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)-The Case of Herbal Medicinal Products Containing St. John's Wort Extracts (SJW).", "Abstract": {"AbstractText": ["Pyrrolizidine alkaloids (PA) exist ubiquitously in our environment. More than 6000 plants, about 3% of the world&rsquo;s flowering plants, are known to synthesize PA. As a consequence, many herbal ingredients, including St. John&rsquo;s wort (SJW), are contaminated with PA that can possess acute and subchronic toxic effects as well as mutagenic and genotoxic properties. Therefore, the possible benefits of SJW as an herbal remedy against depression need to be weighed against the possible risks of unwanted PA intake.", "We searched the literature regarding the current knowledge on PA and evaluated the evidence on the antidepressant effects of quantified SJW extract based on a Cochrane Review and the current practice guidelines on depression. Risks are depicted in form of a risk ladder and benefits in form of an icon array.", "Evidence from clinical studies indicates that quantified SJW extract is an effective treatment option for mild to moderate depression with fewer side effects than conventional antidepressants. Health statistics from different countries do not quantify cases of death caused by PA intake. However, deaths due to suicide, often triggered by depression, are common (11 in 1000 in Germany in 2015) and rank between fatalities due to liver diseases (16 in 1000) and household accidents (10 in 1000).", "Quantified SJW extract is a safe and effective treatment option, and its potential of treating depression outweighs the (hypothetical) risk of unwanted PA intake."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine, LMU-University of Munich, 80336 Munich, Germany. info@michael-habs.de."}], "LastName": "Habs", "ForeName": "Michael", "Initials": "M"}, {"Identifier": ["0000-0003-0416-3029"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Didactics of Mathematics, University of Regensburg, 93053 Regensburg, Germany. karin.binder@mathematik.uni-regensburg.de."}], "LastName": "Binder", "ForeName": "Karin", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Didactics of Mathematics, University of Regensburg, 93053 Regensburg, Germany. stefan.krauss@mathematik.uni-regensburg.de."}], "LastName": "Krauss", "ForeName": "Stefan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany. karolina.mueller@ukr.de."}], "LastName": "M\u00fcller", "ForeName": "Karolina", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "General Medicine Unit, University Hospital Regensburg, 93053 Regensburg, Germany. dr.b.ernst@t-online.de."}], "LastName": "Ernst", "ForeName": "Brigitte", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Evidence-Based Dietetics, University of Applied Sciences Neubrandenburg, 17033 Neubrandenburg, Germany. valentini@hs-nb.de."}], "LastName": "Valentini", "ForeName": "Luzia", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany. michael.koller@ukr.de."}], "LastName": "Koller", "ForeName": "Michael", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Nutrients", "NlmUniqueID": "101521595", "ISSNLinking": "2072-6643"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antidepressive Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrrolizidine Alkaloids"}], "MeshHeadingList": [{"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Antidepressive Agents"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Depression"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Hypericum"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Pyrrolizidine Alkaloids"}, {"QualifierName": [], "DescriptorName": "Risk Assessment"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Wiedenfeld H., Roeder E., Bourauel T., Edgar J.A. Pyrrolizidine Alkaloids: Structure and Toxicity. V&R Unipress; G\u00f6ttingen, Germany: 2008."}, {"Citation": "Bundesinstitut f\u00fcr Risikobewertung  Frequently Asked Questions on Pyrrolizidine Alkaloids in Foods.  [(accessed on 11 May 2017)];2016  Available online:  http://www.bfr.bund.de/cm/349/frequently-asked-questions-on-pyrrolizidine-alkaloids-in-foods.pdf."}, {"Citation": "Merz K., Schrenk D. Interim relative potency factors for the toxicological risk assessment of pyrrolizidine alkaloids in food and herbal medicines. Toxicol. Lett. 2016;263:44\u201357. doi: 10.1016/j.toxlet.2016.05.002.", "ArticleIdList": ["10.1016/j.toxlet.2016.05.002", "27157086"]}, {"Citation": "Habs M., Binder K., Krauss S., M\u00fcller K., Ernst B., Valentini L., Koller M. A balanced risk-benefit analysis to determine human risks associated with Pyrrolizidine Alkaloids (PA)-The case of tea and herbal infusions. Nutrients. 2017;9:717. doi: 10.3390/nu9070717.", "ArticleIdList": ["10.3390/nu9070717", "PMC5537832", "28686224"]}, {"Citation": "European Medicines Agency  Public Statement on the Use of Herbal Medicinal Products Containing Toxic, Unsaturated Pyrrolizidine Alkaloids (PAs)  [(accessed on 9 May 2017)];2014  Available online:  http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2014/12/WC500179559.pdf."}, {"Citation": "Mulder P.P., S\u00e1nchez P.L., These A., Preiss-Weigert A., Castellari M. Occurrence of Pyrrolizidine Alkaloids in food. EFSA Support. Publ. 2015;12 doi: 10.2903/sp.efsa.2015.EN-859.", "ArticleIdList": ["10.2903/sp.efsa.2015.EN-859"]}, {"Citation": "Hidaka B.H. Depression as a disease of modernity: Explanations for increasing prevalence. J. Affect. Disord. 2012;140:205\u2013214. doi: 10.1016/j.jad.2011.12.036.", "ArticleIdList": ["10.1016/j.jad.2011.12.036", "PMC3330161", "22244375"]}, {"Citation": "P\u00f6ldinger W. Zur Geschichte des Johanniskrauts. Praxis. 2000;89:2102\u20132109.", "ArticleIdList": ["11155493"]}, {"Citation": "European Medicines Agency, Committee on Herbal Medicinal Products (HMPC)  Community Herbal Monograph on Hypericum perforatium L., Herba (Well-Established Medicinal Use)  [(accessed on 9 May 2017)];2009  Available online:  http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2010/01/WC500059145.pdf."}, {"Citation": "National Institute for Health and Care Excellence (NICE)  Depression in Adults with a Chronic Physical Health Problem: Recognition and Management.  [(accessed on 9 May 2017)];2009  Available online:  https://www.nice.org.uk/guidance/cG91."}, {"Citation": "Linde K., Berner M.M., Kriston L. St John\u2019s wort for major depression. Cochrane Libr. 2008;4 doi: 10.1002/14651858.CD000448.pub3.", "ArticleIdList": ["10.1002/14651858.CD000448.pub3", "PMC7032678", "18843608"]}, {"Citation": "European Medicines Agency, Committee on Herbal Medicinal Product  Community Herbal Monograph on Hypericum perforatium L., Herba (Traditional Use)  [(accessed on 30 March 2018)];2009  Available online:  http://www.ema.europa.eu/docs/en_GB/document_library/Herbal__Community_herbal_monograph/2010/01/WC500059149.pdf."}, {"Citation": "Greeson J.M., Sanford B., Monti D.A. St. John\u2019s wort (Hypericum perforatum): A review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology. 2001;153:402\u2013414. doi: 10.1007/s002130000625.", "ArticleIdList": ["10.1007/s002130000625", "11243487"]}, {"Citation": "M\u00fcller W. Current St. John\u2019s wort research from mode of action to clinical efficacy. Pharmacol. Res. 2003;47:101\u2013109. doi: 10.1016/S1043-6618(02)00266-9.", "ArticleIdList": ["10.1016/S1043-6618(02)00266-9", "12543057"]}, {"Citation": "Butterweck V. Mechanism of action of St John\u2019s wort in depression: What is known? CNS Drugs. 2003;17:539\u2013562. doi: 10.2165/00023210-200317080-00001.", "ArticleIdList": ["10.2165/00023210-200317080-00001", "12775192"]}, {"Citation": "Apaydin E.A., Maher A.R., Shanman R., Booth M.S., Miles J.N., Sorbero M.E., Hempel S. A systematic review of St. John\u2019s wort for major depressive disorder. Syst. Rev. 2016;5:148. doi: 10.1186/s13643-016-0325-2.", "ArticleIdList": ["10.1186/s13643-016-0325-2", "PMC5010734", "27589952"]}, {"Citation": "Cui Y., Zheng Y. A meta-analysis on the efficacy and safety of St John\u2019s wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults. Neuropsychiatr. Dis. Treat. 2016;12:1715\u20131723. doi: 10.2147/NDT.S106752.", "ArticleIdList": ["10.2147/NDT.S106752", "PMC4946846", "27468236"]}, {"Citation": "National Center for Complementary and Integrative Health  St. John\u2019s Wort.  [(accessed on 26 November 2017)];2017  Available online:  https://nccih.nih.gov/health/stjohnswort."}, {"Citation": "Hypericum Depression Trial Study Group Effect of Hypericum perforatum (St John\u2019s Wort) in Major Depressive Disorder. JAMA. 2002;287:1807\u20131814. doi: 10.1001/jama.287.14.1807.", "ArticleIdList": ["10.1001/jama.287.14.1807", "11939866"]}, {"Citation": "Rapaport M.H., Nierenberg A.A., Howland R., Dording C., Schettler P.J., Mischoulon D. The treatment of minor depression with St. John\u2019s Wort or citalopram: Failure to show benefit over placebo. J. Psychiatr. Res. 2011;45:931\u2013941. doi: 10.1016/j.jpsychires.2011.05.001.", "ArticleIdList": ["10.1016/j.jpsychires.2011.05.001", "PMC3137264", "21632064"]}, {"Citation": "Henderson L., Yue Q.Y., Bergquist C., Gerden B., Arlett P. St John\u2019s wort (Hypericum perforatum): Drug interactions and clinical outcomes. Br. J. Clin. Pharmacol. 2002;54:349\u2013356. doi: 10.1046/j.1365-2125.2002.01683.x.", "ArticleIdList": ["10.1046/j.1365-2125.2002.01683.x", "PMC1874438", "12392581"]}, {"Citation": "Mannel M. Drug interactions with St John\u2019s wort: Mechanisms and clinical implications. Drug Saf. 2004;27:773\u2013797. doi: 10.2165/00002018-200427110-00003.", "ArticleIdList": ["10.2165/00002018-200427110-00003", "15350151"]}, {"Citation": "Izzo A.A. Drug interactions with St. John\u2019s Wort (Hypericum perforatum): A review of the clinical evidence. Int. J. Clin. Pharmacol. Ther. 2004;42:139\u2013148. doi: 10.5414/CPP42139.", "ArticleIdList": ["10.5414/CPP42139", "15049433"]}, {"Citation": "Borrelli F., Izzo A.A. Herb-drug interactions with St John\u2019s wort (Hypericum perforatum): An update on clinical observations. AAPS J. 2009;11:710\u2013727. doi: 10.1208/s12248-009-9146-8.", "ArticleIdList": ["10.1208/s12248-009-9146-8", "PMC2782080", "19859815"]}, {"Citation": "Soleymani S., Bahramsoltani R., Rahimi R., Abdollahi M. Clinical risks of St John\u2019s Wort (Hypericum perforatum) co-administration. Expert Opin. Drug Metab. Toxicol. 2017;13:1047\u20131062. doi: 10.1080/17425255.2017.1378342.", "ArticleIdList": ["10.1080/17425255.2017.1378342", "28885074"]}, {"Citation": "Brockm\u00f6ller J., Reum T., Bauer S., Kerb R., H\u00fcbner W.D., Roots I. Hypericin and pseudohypericin: Pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry. 1997;30:94\u2013101. doi: 10.1055/s-2007-979527.", "ArticleIdList": ["10.1055/s-2007-979527", "9342768"]}, {"Citation": "Edwards S.E., da Costa Rocha I., Heinrich M., Williamson E.M. Phytopharmacy: An Evidence-Based Guide to Herbal Medicinal Products. Wiley Blackwell; Chichester, UK: 2015."}, {"Citation": "S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung.  [(accessed on 9 May 2017)]; Available online:  https://www.leitlinien.de/mdb/downloads/nvl/depression/archiv/depression-1aufl-vers5-lang.pdf."}, {"Citation": "Kasper S., Caraci F., Forti B., Drago F., Aguglia E. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur. Neuropsychopharmacol. 2010;20:747\u2013765. doi: 10.1016/j.euroneuro.2010.07.005.", "ArticleIdList": ["10.1016/j.euroneuro.2010.07.005", "20708905"]}, {"Citation": "Qaseem A., Barry M.J., Kansagara D. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: A clinical practice guideline from the american college of physicians. Ann. Intern. Med. 2016;164:350\u2013359. doi: 10.7326/M15-2570.", "ArticleIdList": ["10.7326/M15-2570", "26857948"]}, {"Citation": "Kempf M., Wittig M., Sch\u00f6nfeld K., Cramer L., Schreier P., Beuerle T. Pyrrolizidine alkaloids in food: Downstream contamination in the food chain caused by honey and pollen. Food Addit. Contam. Part A Chem. Anal. Control. Expo. Risk Assess. 2011;28:325\u2013331. doi: 10.1080/19440049.2010.521771.", "ArticleIdList": ["10.1080/19440049.2010.521771", "20967664"]}, {"Citation": "Knutsen H.K., Alexander J., Barreg\u00e5rd L., Bignami M., Br\u00fcschweiler B., Ceccatelli S., Cottrill B., Dinovi M., Edler L., Grasl-Kraupp B., et al. Risks for human health related to the presence of pyrrolizidine alkaloids in honey, tea, herbal infusions and food supplements. EFSA J. 2017;15:292. doi: 10.2903/j.efsa.2017.4908.", "ArticleIdList": ["10.2903/j.efsa.2017.4908", "PMC7010083", "32625569"]}, {"Citation": "Roeder E. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie. 1995;50:83\u201398.", "ArticleIdList": ["7700976"]}, {"Citation": "European Food Safety Authority Dietary exposure assessment to pyrrolizidine alkaloids in the European population. EFSA J. 2016;14:e04572. doi: 10.2903/j.efsa.2016.4572.", "ArticleIdList": ["10.2903/j.efsa.2016.4572"]}, {"Citation": "European Medicines Agency  Public Statement on Contamination of Herbal Medicinal Products/Traditional Herbal Medicinal Products with Pyrrolizidine Alkaloids: Transitional Recommendations for Risk Management and Quality Control.  [(accessed on 9 May 2017)];2016  Available online:  http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2016/06/WC500208195.pdf."}, {"Citation": "Gov.uk  Precautionary Recall-Six Batches of St John\u2019s Wort Tablets.  [(accessed on December 2017)];2016  Available online:  https://www.gov.uk/government/news/precautionary-recall-six-batches-of-st-johns-wort-tablets."}, {"Citation": "Letsyo E., Jerz G., Winterhalter P., Lindigkeit R., Beuerle T. Incidence of pyrrolizidine alkaloids in herbal medicines from German retail markets: Risk assessments and implications to consumers. Phytother. Res. 2017;31:1903\u20131909. doi: 10.1002/ptr.5935.", "ArticleIdList": ["10.1002/ptr.5935", "28960556"]}, {"Citation": "Lechtenberger M., Hensel A., Steinhoff B. Hepatotoxisch und karzinogen: Pyrrolizidinalalkaloide in Arznei- und Lebensmitteln sorgen f\u00fcr Probleme. Deut. Apoth. Ztg. 2017;157:32\u201341."}, {"Citation": "Code of Practice to Prevent and Reduce Pyrrolizidine Alkaloid Contaminations of Medicinal Products of Plant Origin.  [(accessed on 9 May 2017)];2016  Available online:  http://203.187.160.133:9011/ehtpa.eu/c3pr90ntc0td/pdf/cop-revision-20090245.pdf."}, {"Citation": "Bundesinstitut f\u00fcr Risikobewertung  Pyrrolizidine Alkaloids (PA)  [(accessed on 20 March 2018)]; Available online:  http://www.bfr.bund.de/en/pyrrolizidine_alkaloids__pa_-192924.html."}, {"Citation": "European Food Safety Authority (EFSA) Panel on Contaminants in the Food Chain Scientific Opinion on Pyrrolizidine alkaloids in food and feed. EFSA J. 2011;9:2406. doi: 10.2903/j.efsa.2011.2406.", "ArticleIdList": ["10.2903/j.efsa.2011.2406"]}, {"Citation": "Crews C., Berthiller F., Krska R. Update on analytical methods for toxic pyrrolizidine alkaloids. Anal. Bioanal. Chem. 2010;396:327\u2013338. doi: 10.1007/s00216-009-3092-2.", "ArticleIdList": ["10.1007/s00216-009-3092-2", "19763547"]}, {"Citation": "Bundesinstitut f\u00fcr Risikobewertung  Vorl\u00e4ufige Empfehlungen des BfR zur Analytik von Pyrrolizidinalkaloiden (PA) in Kr\u00e4utertee und Tee Analytspektrum und Probenahmeverfahren)  [(accessed on 11 May 2017)];2016  Available online:  http://www.bfr.bund.de/cm/343/vorlaeufige-empfehlungen-des-bfr-zur-analytik-von-pyrrolizidinalkaloiden-pa-in-kraeutertee-und-tee.pdf."}, {"Citation": "De Nijs M., Elbers I.J.W., Mulder P.P.J. Inter-laboratory comparison study for pyrrolizidine alkaloids in animal feed using spiked and incurred material. Food Addit. Contam. Part A Chem. Anal. Control. Expo. Risk Assess. 2014;31:288\u2013299. doi: 10.1080/19440049.2013.871757.", "ArticleIdList": ["10.1080/19440049.2013.871757", "24303804"]}, {"Citation": "Bodi D., Pydde Y., Prei\u00df-Weigert A. Internationale Laborvergleichsuntersuchung zur Bestimmung von Pyrrolizidinalkaloiden in Kr\u00e4utertee und Rooibostee. BfR-Wissenschaft; Berlin, Germany: 2016."}, {"Citation": "Committee on Herbal Medicinal Product  Guideline on Good Agricultural and Collecting Practice (GACP) for Starting Material of Herbal Origin.  [(accessed on 11 May 2017)];2006  Available online:  http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003362.pdf."}, {"Citation": "Pawar R.S. Bad Bug Book: Foodborne Pathogenic Microorganisms and Natural Toxins. Volume 2. Food and Drug Administration; Silver Spring, MD, USA: 2012. Pyrrolizidine alkaloids; pp. 242\u2013244."}, {"Citation": "Ruan J., Yang M., Fu P., Ye Y., Lin G. Metabolic activation of pyrrolizidine alkaloids: Insights into the structural and enzymatic basis. Chem. Res. Toxicol. 2014;27:1030\u20131039. doi: 10.1021/tx500071q.", "ArticleIdList": ["10.1021/tx500071q", "24836403"]}, {"Citation": "Cohen S.M., Storer R.D., Criswell K.A., Doerrer N.G., Dellarco V.L., Pegg D.G., Wojcinski Z.W., Malarkey D.E., Jacobs A.C., Klaunig J.E., et al. Hemangiosarcoma in rodents: Mode-of-action evaluation and human relevance. Toxicol. Sci. 2009;111:4\u201318. doi: 10.1093/toxsci/kfp131.", "ArticleIdList": ["10.1093/toxsci/kfp131", "19525443"]}, {"Citation": "Guo L., Mei N., Xia Q., Chen T., Chan P.C., Fu P.P. Gene expression profiling as an initial approach for mechanistic studies of toxicity and tumorigenicity of herbal plants and herbal dietary supplements. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2010;28:60\u201387. doi: 10.1080/10590500903585416.", "ArticleIdList": ["10.1080/10590500903585416", "PMC5736312", "20390968"]}, {"Citation": "Rasenack R., Muller C., Kleinschmidt M., Rasenack J., Wiedenfeld H. Veno-occlusive disease in a fetus caused by pyrrolizidine alkaloids of food origin. Fetal Diagn. Ther. 2003;18:223\u2013225. doi: 10.1159/000070799.", "ArticleIdList": ["10.1159/000070799", "12835579"]}, {"Citation": "DeLeve L.D., McCuskey R.S., Wang X., Hu L., McCuskey M.K., Epstein R.B., Kanel G.C. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 1999;29:1779\u20131791. doi: 10.1002/hep.510290615.", "ArticleIdList": ["10.1002/hep.510290615", "10347121"]}, {"Citation": "Kakar F., Akbarian Z., Leslie T., Mustafa M.L., Watson J., van Egmond H.P., Omar M.F., Mofleh J. An outbreak of hepatic veno-occlusive disease in Western Afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids. J. Toxicol. 2010;2010:313280. doi: 10.1155/2010/313280.", "ArticleIdList": ["10.1155/2010/313280", "PMC2905904", "20652038"]}, {"Citation": "Wiedenfeld H. Aufnahmewege von PA Durch Direkte und Indirekte Intoxikation.  [(accessed on 11 May 2017)]; Available online:  https://www.ak-kreuzkraut.de/toxizit\u00e4t-mensch-tier/humangef\u00e4hrdung/aufnahmewege/"}, {"Citation": "Carpenter D.O., Bushkin-Bedient S. Exposure to chemicals and radiation during childhood and risk for cancer later in life. J. Adolesc. Health. 2013;52:S21\u2013S29. doi: 10.1016/j.jadohealth.2013.01.027.", "ArticleIdList": ["10.1016/j.jadohealth.2013.01.027", "23601608"]}, {"Citation": "Wiedenfeld H. Plants containing pyrrolizidine alkaloids: Toxicity and problems. Food Addit. Contam. Part A Chem. Anal. Control. Expo. Risk Assess. 2011;28:282\u2013292. doi: 10.1080/19440049.2010.541288.", "ArticleIdList": ["10.1080/19440049.2010.541288", "21360374"]}, {"Citation": "IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. World Health Organization. International Agency for Research on Cancer. ebrary, Inc. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Press; Lyon, France: 2002. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene.", "ArticleIdList": ["PMC4781602", "12687954"]}, {"Citation": "International Agency for Research on Cancer . IARC Monographs on the Evaluation of Carcinogenic Risks of Chemicals to Man. International Agency for Research on Cancer; Lyon, France: 1976. Some naturally occurring substances."}, {"Citation": "International Agency for Research on Cancer. IARC Working Group on the Evaluation of the Carcinogenic Risk of Chemicals to Humans . IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. IARC; Lyon, France: 1983. Some food additives, feed additives and naturally occurring substances.", "ArticleIdList": ["6579000"]}, {"Citation": "Xia Q., Yan J., Chou M.W., Fu P.P. Formation of DHP-derived DNA adducts from metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, heliotrine. Toxicol. Lett. 2008;178:77\u201382. doi: 10.1016/j.toxlet.2008.02.008.", "ArticleIdList": ["10.1016/j.toxlet.2008.02.008", "18395999"]}, {"Citation": "Fu P.P., Yang Y., Xia Q., Chou M.W., Cui Y.Y., Lin G. Pyrrolizidine Alkaloids: Tumorigenic Components in Chinese Herbal Medicines and Dietary Supplements. J. Food Drug Anal. 2002;10:198\u2013211."}, {"Citation": "Habs H., Habs M., Marquardt H., R\u00f6der E., Schm\u00e4hl D., Wiedenfeld H. Carcinogenic and mutagenic activity of an alkaloidal extract of Senecio nemorensis ssp. fuchsii. Arzneim. Forsch. 1982;32:144\u2013148.", "ArticleIdList": ["7199918"]}, {"Citation": "National Toxicology Program  Final Report on Carcinogens Background Document for Riddelliine.  [(accessed on 9 May 2017)];2008  Available online:  https://ntp.niehs.nih.gov/ntp/roc/twelfth/2010/finalbds/riddelliine_final_508.pdf.", "ArticleIdList": ["20737008"]}, {"Citation": "International Agency for Research on Cancer . IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Chemical Agents and Related Occupations, Volume 100F. A Review of Human Carcinogens. IARC; Lyon, France: 2012.", "ArticleIdList": ["PMC4781612", "23189753"]}, {"Citation": "Hong C.B., Winston J.M., Lee C.C. Hepatic angiosarcoma: Animal model: Angiosarcoma of rats and mice induced by vinyl chloride. Am. J. Pathol. 1980;101:737\u2013740.", "ArticleIdList": ["PMC1903657", "7192493"]}, {"Citation": "Falk H., Herbert J., Crowley S., Ishak K.G., Thomas L.B., Popper H., Caldwell G.G. Epidemiology of hepatic angiosarcoma in the United States: 1964\u20131974. Environ. Health Perspect. 1981;41:107\u2013113. doi: 10.1289/ehp.8141107.", "ArticleIdList": ["10.1289/ehp.8141107", "PMC1568861", "7199426"]}, {"Citation": "Huang N., Wann S., Chang H., Lin S.L., Wang J.S., Guo H.R. Arsenic, vinyl chloride, viral hepatitis, and hepatic angiosarcoma: A hospital-based study and review of literature in Taiwan. BMC Gastroenterol. 2011;11:142. doi: 10.1186/1471-230X-11-142.", "ArticleIdList": ["10.1186/1471-230X-11-142", "PMC3280174", "22200164"]}, {"Citation": "Zheng Y., Zhang X., Zhang J., Hui Z.Z., Du W.J., Li R.M., Ren X.B. Primary hepatic angiosarcoma and potential treatment options. J. Gastroenterol. Hepatol. 2014;29:906\u2013911. doi: 10.1111/jgh.12506.", "ArticleIdList": ["10.1111/jgh.12506", "24372769"]}, {"Citation": "Zocchetti C. Angiosarcoma del fegato nell\u2019uomo: Considerazioni epidemiologiche (Liver angiosarcoma in humans: Epidemiologic considerations) Med. Lav. 2001;92:39\u201353.", "ArticleIdList": ["11367826"]}, {"Citation": "Chiou H.Y., Hsueh Y.M., Liaw K.F., Horng S.F., Chiang M.H., Pu Y.S., Lin J.S., Huang C.H., Chen C.J. Incidence of internal cancers and ingested inorganic arsenic: A seven-year follow-up study in Taiwan. Cancer Res. 1995;55:1296\u20131300.", "ArticleIdList": ["7882325"]}, {"Citation": "Falk H., Thomas L.B., Popper H., Ishak K. Hepatic angiosarcoma associated with androgenic-anabolic steroids. Lancet. 1979;314:1120\u20131123. doi: 10.1016/S0140-6736(79)92515-7.", "ArticleIdList": ["10.1016/S0140-6736(79)92515-7", "91848"]}, {"Citation": "Spiegelhalter D., Pearson M., Short I. Visualizing uncertainty about the future. Science. 2011;333:1393\u20131400. doi: 10.1126/science.1191181.", "ArticleIdList": ["10.1126/science.1191181", "21903802"]}, {"Citation": "Gigerenzer G. Why does framing influence judgment? J. Gen. Intern. Med. 2003;18:960\u2013961. doi: 10.1046/j.1525-1497.2003.30901.x.", "ArticleIdList": ["10.1046/j.1525-1497.2003.30901.x", "PMC1494941", "14687283"]}, {"Citation": "Spiegelhalter D.J. Understanding uncertainty. Ann. Fam. Med. 2008;6:196\u2013197. doi: 10.1370/afm.848.", "ArticleIdList": ["10.1370/afm.848", "PMC2384984", "18474880"]}, {"Citation": "Gao H., Ruan J.Q., Chen J., Li N., Ke C.Q., Ye Y., Lin G., Wang J.Y. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des. Dev. Ther. 2015;25:4861\u20134868. doi: 10.2147/DDDT.S87858.", "ArticleIdList": ["10.2147/DDDT.S87858", "PMC4554430", "26346783"]}, {"Citation": "Prakash A.S., Pereira T.N., Reilly P.E., Seawright A.A. Pyrrolizidine alkaloids in human diet. Mutat. Res. 1999;443:53\u201367. doi: 10.1016/S1383-5742(99)00010-1.", "ArticleIdList": ["10.1016/S1383-5742(99)00010-1", "10415431"]}, {"Citation": "Altman D.G., Bland J.M. Statistics notes: Absence of evidence is not evidence of absence. BMJ. 1995;311:485. doi: 10.1136/bmj.311.7003.485.", "ArticleIdList": ["10.1136/bmj.311.7003.485", "PMC2550545", "7647644"]}, {"Citation": "American Cancer Society Liver Cancer Risk Factors.  [(accessed on December 2017)]; Available online:  https://www.cancer.org/cancer/liver-cancer/causes-risks-prevention/risk-factors.html."}, {"Citation": "Tversky A., Kahneman D. Availability: A heuristic for judging frequency and probability. Cogn. Psychol. 1973;5:207\u2013232. doi: 10.1016/0010-0285(73)90033-9.", "ArticleIdList": ["10.1016/0010-0285(73)90033-9"]}, {"Citation": "Statistisches Bundesamt  Gesundheit: Todesursachen in Deutschland 2015.  [(accessed on 1 April 2017)];2017  Available online:  https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Todesursachen/Todesursachen.html."}, {"Citation": "bfu-Swiss Council for Accident Prevention  Status 2017: Statistics on Non-Occupational Accidents and the Level of Safety in Switzerland.  [(accessed on 9 May 2017)];2017  Available online:  https://www.bfu.ch/sites/assets/Shop/bfu_2.287.08_STATUS%202017%20%E2%80%93%20Statistics%20on%20non-occupational%20accidents%20and%20the%20level%20of%20safety%20in%20Switzerland.pdf."}, {"Citation": "Naghavi M., Abajobir A.A., Abbafati C., Abbas K.M., Abd-Allah F., Abera S.F., Aboyans V., Adetokunboh O., Afshin A., Agrawal A., et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151\u20131210. doi: 10.1016/S0140-6736(17)32152-9.", "ArticleIdList": ["10.1016/S0140-6736(17)32152-9", "PMC5605883", "28919116"]}, {"Citation": "Galesic M., Garcia-Retamero R., Gigerenzer G. Using icon arrays to communicate medical risks: Overcoming low numeracy. Health Psychol. 2009;28:210\u2013216. doi: 10.1037/a0014474.", "ArticleIdList": ["10.1037/a0014474", "19290713"]}, {"Citation": "McDowell M., Rebitschek F.G., Gigerenzer G., Wegwarth O. A Simple Tool for Communicating the Benefits and Harms of Health Interventions. MDM Policy Pract. 2016;1:1\u201310. doi: 10.1177/2381468316665365.", "ArticleIdList": ["10.1177/2381468316665365", "PMC6125040", "30288405"]}, {"Citation": "Keller C. Using a familiar risk comparison within a risk ladder to improve risk understanding by low numerates: A study of visual attention. Risk Anal. 2011;31:1043\u20131054. doi: 10.1111/j.1539-6924.2010.01577.x.", "ArticleIdList": ["10.1111/j.1539-6924.2010.01577.x", "21284684"]}, {"Citation": "Reeves A. Working with Risk in Counselling and Psychotherapy. SAGE Press; Newcastle upon Tyne, UK: 2015. Essential Issues in Counselling and Psychotherapy."}, {"Citation": "Gaynes B.N., West S.L., Ford C.A., Frame P., Klein J., Lohr K.N. Screening for suicide risk in adults: A summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2004;140:822\u2013835. doi: 10.7326/0003-4819-140-10-200405180-00015.", "ArticleIdList": ["10.7326/0003-4819-140-10-200405180-00015", "15148072"]}, {"Citation": "Ng C.W.M., How C.H., Ng Y.P. Depression in primary care: Assessing suicide risk. Singap. Med. J. 2017;58:72\u201377. doi: 10.11622/smedj.2017006.", "ArticleIdList": ["10.11622/smedj.2017006", "PMC5311887", "28210741"]}, {"Citation": "Nischal A., Tripathi A., Nischal A., Trivedi J.K. Suicide and antidepressants: What current evidence indicates. Mens Sana Monogr. 2012;10:33\u201344. doi: 10.4103/0973-1229.87287.", "ArticleIdList": ["10.4103/0973-1229.87287", "PMC3353604", "22654381"]}, {"Citation": "Cipriani A., Furukawa T.A., Salanti G., Chaimani A., Atkinson L.Z., Ogawa Y., Leucht S., Ruhe H.G., Turner E.H., Higgins J.P., et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet. 2018;391:1357\u20131366. doi: 10.1016/S0140-6736(17)32802-7.", "ArticleIdList": ["10.1016/S0140-6736(17)32802-7", "PMC5889788", "29477251"]}, {"Citation": "Rahimi R., Nikfar S., Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2009;33:118\u2013127. doi: 10.1016/j.pnpbp.2008.10.018.", "ArticleIdList": ["10.1016/j.pnpbp.2008.10.018", "19028540"]}]}], "History": [{"Year": "2018", "Month": "5", "Day": "18"}, {"Year": "2018", "Month": "6", "Day": "8"}, {"Year": "2018", "Month": "6", "Day": "19"}, {"Year": "2018", "Month": "6", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "6", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "1", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "7", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["29932143", "PMC6073194", "10.3390/nu10070804", "nu10070804"]}}]}